

Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question?

Priyanka Bhateja, Neelesh Sharma

Department of Hematology/Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA

Correspondence to: Neelesh Sharma, MD, PhD. Assistant Professor, Department of Thoracic Oncology, University Hospitals/Case Comprehensive Cancer Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106-1716, USA. Email: neelesh.sharma@uhhospitals.org.

Submitted Aug 12, 2016. Accepted for publication Aug 18, 2016.

doi: 10.21037/atm.2016.09.45

View this article at: <http://dx.doi.org/10.21037/atm.2016.09.45>

Epidermal growth factor receptor (*EGFR*) mutations occur in about 5–10% of non-small cell lung cancer (NSCLC) in non-Asian population and 40–45% Asian population (1,2). Activating *EGFR* mutations (exon 19 deletion or *L858R* substitution in exon 21) predict high response rate to first line *EGFR* tyrosine kinase inhibitors (*EGFR*-TKIs). Approved *EGFR*-TKI's for the treatment of *EGFR* mutant lung cancer include first generation TKIs (erlotinib and gefitinib) and second generation TKI (afatinib). Third generation *EGFR*-TKIs have also been developed to target resistance mutation T790M and spare wild type *EGFR*. Afatinib is an irreversible ERB family blocker that potently inhibits signaling of all homodimers and heterodimers formed by the *EGFR*, human epidermal growth factor receptor (HER)-2, HER-3, and HER-4 receptors. Afatinib has been evaluated in various settings in LUX-Lung trials summarized in Table 1 (3-9). A subgroup pooled analysis of LUX-Lung 3 and LUX-Lung 6 showed a survival advantage of afatinib over chemotherapy in patients with exon 19 deletion (10).

After an initial response to *EGFR*-TKIs, resistance develops invariably through various mechanisms including T790M mutations (50–60% of patients), *MET* amplification, epithelial to mesenchymal transformation, *HER-2* amplification or transformation to small cell lung cancer (11). Development of acquired resistance is heterogeneous process with multiple mechanisms of resistance developing at separate metastatic sites in same patient or at the same site at different time points. Therefore, it is possible that radiographic progression at one site may not imply that all other sites would also be

resistant to *EGFR*-TKI. Supporting this hypothesis, a flare phenomenon has been reported where discontinuation of *EGFR*-TKI for radiological progression, results in rapid, symptomatic progression at other sites attributed to presence of TKI sensitive clones (12). This phenomenon has given rise to concept of continuing *EGFR*-TKI beyond progression. Multiple retrospective studies have shown that *EGFR*-TKI can be continued beyond progression in combination with loco-regional (surgery, radiation) treatment or chemotherapy and may lead to better outcomes (13,14).

In the phase III LUX-Lung 5 trial (15), published in *Annals of Oncology*, Schuler *et al.* evaluated whether continuation of afatinib with paclitaxel is superior to paclitaxel alone after progression on *EGFR*-TKI in a cohort of lung cancer patients clinically enriched for *EGFR* dependency. The trial was conducted in two parts: part A enrolled patients who had progressed on one or more chemotherapy regimen, had a clinical benefit (complete response, partial response or stable disease) of ≥ 12 weeks on first generation *EGFR*-TKI (erlotinib or gefitinib) and must have attained ≥ 12 weeks of clinical benefit on afatinib monotherapy with subsequent radiologic progression. The patients weren't screened for *EGFR* mutation status as it was not standard clinical practice at the time of study planning but were clinically enriched based on disease control with *EGFR*-TKI for ≥ 12 weeks. Patients in part A, who derived clinical benefit from afatinib monotherapy were then screened for randomization in 2:1 fashion to afatinib plus paclitaxel (based on pre-clinical evidence of synergism) versus dealer's choice chemotherapy (part

Table 1 LUX-Lung trials evaluating afatinib in various settings

Study	Study design	Patient population	Treatment arms	Primary endpoint	Results
LUX-Lung 1	Phase 2b/3 randomized	<i>EGFR</i> + progressed on first generation <i>EGFR</i> -TKI (n=595)	Afatinib vs. placebo	OS	10.8 vs. 12 months (HR =1.08, 95% CI: 0.86–1.35; P=0.74)
LUX-Lung 2	Phase 2 single arm	Second line or higher <i>EGFR</i> positive after chemotherapy (TKI naive) (n=129)	Afatinib	ORR	61%
LUX-Lung 3	Phase 3 randomized	First line <i>EGFR</i> + (n=345), adenocarcinoma	Afatinib vs. cisplatin plus pemetrexed	PFS	11.1 vs. 6.9 months (HR =0.58, 95% CI: 0.34–0.65, P=0.001)
LUX-Lung 4	Phase 2 single arm	Adenocarcinoma progressed on first generation <i>EGFR</i> -TKI (n=61)	Afatinib	ORR	8.2% (95% CI: 2.7–18.1%)
LUX-Lung 6	Phase 3 randomized	First line <i>EGFR</i> + (n=364)	Afatinib vs. cisplatin plus gemcitabine	PFS	11 vs. 5.6 months (HR =0.28, 95% CI: 0.20–0.39, P<0.0001)
LUX-Lung 7	Phase 2b randomized	First line <i>EGFR</i> + (n=319)	Afatinib vs. gefitinib	Coprietary end points (PFS, OS and TTF)	PFS: 11 vs. 10.9 months (HR =0.73, 95% CI: 0.57–0.95, P=0.017); TTF: 13.7 vs. 11.5 months (HR =0.73, 95% CI: 0.58–0.92, P=0.0073); OS not mature
LUX-Lung 8	Phase 3 randomized	Second line squamous cell (n=795)	Afatinib vs. gefitinib	PFS	2.4 vs. 1.9 months (HR =0.82, 95% CI: 0.68–1, P=0.0427)

HR, hazard ratio; CI, confidence interval; ORR, objective response rate; OS, overall survival; PFS, progression free survival; TTF, time to treatment failure; vs., versus.

B). The primary end point was progression free survival (PFS), secondary endpoints included overall survival (OS) and objective response rate (ORR). The median PFS was significantly longer with afatinib plus chemotherapy versus chemotherapy alone [5.6 vs. 2.8 months, hazard ratio (HR) =0.60, 95% confidence interval (CI): 0.43–0.85, P=0.003]. The median PFS in the chemotherapy alone arm was the longest for paclitaxel (3.8 months). There was no difference in median OS (12.2 months) between the two groups. The ORR was 32.1% in the combination arm versus 13.2% in chemotherapy only arm (OR =3.41, 95% CI: 1.41–6.79, P=0.005).

Authors should be commended for successfully conducting a prospective randomized study in fourth line setting for treatment of lung cancer. The study was designed to address an important question of *EGFR*-TKI continuation beyond progression in combination with chemotherapy and showed that in selected patient population, continued *EGFR* blockade with chemotherapy may improve PFS compared to single agent chemotherapy after progression on *EGFR*-TKI monotherapy. Although

LUX-Lung 5 provides prospective validation of this concept, its reliability and clinical utility is limited due to several factors. The study was underpowered as the initial number of 351 projected patients to part B was considered unachievable and not recruited. Of the 1,154 patients treated with afatinib monotherapy, 223 patients with clinical benefit of 12 weeks were screened and only 202 patients were randomized. Of the 299 patients with progression after initial benefit on afatinib monotherapy most declined participation due to general health deterioration. This high drop out in enrollment after progression on third line afatinib monotherapy suggests that most patients were not able to have subsequent treatment and patients who continued treatment might be part of a selected population with good performance status, low co-morbidity or even different disease biology.

Recently multiple reports have demonstrated that treatment of *EGFR* mutant patients after radiologic progression on *EGFR*-TKI can be complicated by the heterogeneous nature of progression (16,17). Clinical outcomes can be widely variable depending on the subtype

of progression, which can be defined as single site, oligo-sites, central nervous system only, systemic or multi-site and asymptomatic or symptomatic. ASPIRATION was a prospective single arm trial in Asian *EGFR* mutant lung cancer patients, designed to evaluate effect of continuing TKI therapy after radiologic progression at the discretion of physician and patient. Results of this study showed that survival post TKI progression can be increased and systemic chemotherapy delayed for a select group of patients without compromising the OS (18). Although this study was limited by the nature of design, it showed that some patients may continue to have indolent course even after radiologic progression on *EGFR*-TKI. It is possible that most patients who went on to fourth line treatment in LUX-Lung 5 study had less aggressive disease and if patients were not classified based on type of progression, an imbalance in these subgroups between the two post afatinib progression arms could have created the difference in PFS.

Other trials of post progression first generation *EGFR*-TKI continuation with chemotherapy after initial benefit have not shown any advantage compared to chemotherapy alone. Our group had conducted a small randomized phase II study of chemotherapy (pemetrexed or docetaxel) versus chemotherapy plus erlotinib in patients with progression after initial clinical benefit from erlotinib. There was increased toxicity with addition of erlotinib to chemotherapy without any added benefit in response rate (13% *vs.* 16%) or PFS (5.5 *vs.* 4.4 months) (19). Similarly IMPRESS was a large randomized phase III trial investigating the role of continuing gefitinib in combination with chemotherapy for *EGFR* mutant patients after development of acquired resistance to initial treatment with gefitinib. The primary end point for the trial was PFS, which was same in two treatment arms (5.4 months) indicating lack of benefit with addition of gefitinib to chemotherapy (20). However an exploratory subgroup analysis suggested potential clinical benefit from continued gefitinib treatment after progression, if *EGFR T790M* was not found in circulating plasma DNA (21). One could argue that positive results in LUX-Lung 5 are related to use of second generation *EGFR*-TKI with irreversible *EGFR* inhibition and some activity against known mechanism of acquired resistance such as *T790M* mutation or *HER-2* amplification.

The choices of chemotherapy in the chemotherapy only arm (a practical decision as there is no established standard fourth line) between the two arms makes the arms unbalanced. Also 13% of patients in the chemotherapy arm had received the same agent previously. In the absence

of placebo arm, it is difficult to ascertain if chemotherapy alone had any significant effect on progression. Since we know from ASIRATION study that *EGFR*-TKI, when continued beyond progression can delay further tumor growth, it is possible that PFS advantage in the afatinib and paclitaxel arm could be entirely due to afatinib.

Serious treatment related adverse events were more common in the combination arm versus chemotherapy only arm (11% *vs.* 3%). It is interesting to note that 36% of patients in the chemotherapy arm received two additional lines of therapy versus 15% in the combination arm, implying a sizable proportion of patients overall went on to receive six or more lines of treatment, which is uncommon for most lung cancer patients treated outside the clinical trial.

LUX-Lung 5 study was more relevant at the time when it was conceived, since then multiple new agents have been approved or are in clinical trial for *EGFR* mutant patients with acquired resistance. Third generation *EGFR*-TKIs are the treatment of choice for patients with *EGFR T790M* mutations based on high response rate (61% and PFS of 9.6 months) and low toxicity secondary to sparing of wild type *EGFR* (22). Osimertinib is approved after progression on first or second generation *EGFR*-TKI in patients with *T790M* mutation. For those patients with non-*T790M* mediated resistance, combination of afatinib and cetuximab (23) has shown a response rate of about 30%.

Ideal future studies on patients with *EGFR* mutations should focus on preventing or delaying emergence of resistance and identifying targets for new resistance mechanisms. The LUX-Lung 5 study with its limitations of being underpowered amongst others is unlikely to find afatinib a new niche.

Acknowledgements

None.

Footnote

Provenance: This is a Guest Commentary commissioned by Section Editor Jianrong Zhang, MD (Department of Thoracic Surgery, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Disease, Guangzhou, China).

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on: Schuler M, Yang JC, Park K, *et al.* Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. *Ann Oncol* 2016;27:417-23.

References

1. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014;511:543-50.
2. Marchetti A, Martella C, Felicioni L, *et al.* EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. *J Clin Oncol* 2005;23:857-65.
3. Miller VA, Hirsh V, Cadranel J, *et al.* Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. *Lancet Oncol* 2012;13:528-38.
4. Yang JC, Shih JY, Su WC, *et al.* Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. *Lancet Oncol* 2012;13:539-48.
5. Katakami N, Atagi S, Goto K, *et al.* LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. *J Clin Oncol* 2013;31:3335-41.
6. Sequist LV, Yang JC, Yamamoto N, *et al.* Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol* 2013;31:3327-34.
7. Wu YL, Zhou C, Hu CP, *et al.* Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *Lancet Oncol* 2014;15:213-22.
8. Soria JC, Felip E, Cobo M, *et al.* Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. *Lancet Oncol* 2015;16:897-907.
9. Park K, Tan EH, O'Byrne K, *et al.* Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *Lancet Oncol* 2016;17:577-89.
10. Yang JC, Wu YL, Schuler M, *et al.* Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol* 2015;16:141-51.
11. Lin Y, Wang X, Jin H. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. *Am J Cancer Res* 2014;4:411-35.
12. Chaft JE, Oxnard GR, Sima CS, *et al.* Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. *Clin Cancer Res* 2011;17:6298-303.
13. Oxnard GR, Lo P, Jackman DM, *et al.* Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR mutant lung cancer. *J Clin Oncol* 2012;30:abstr 7547.
14. Nishie K, Kawaguchi T, Tamiya A, *et al.* Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. *J Thorac Oncol* 2012;7:1722-7.
15. Schuler M, Yang JC, Park K, *et al.* Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. *Ann Oncol* 2016;27:417-23.
16. Gandara DR, Li T, Lara PN, *et al.* Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. *Clin Lung Cancer* 2014;15:1-6.
17. Weickhardt AJ, Scheier B, Burke JM, *et al.* Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. *J Thorac Oncol* 2012;7:1807-14.
18. Park K, Yu CJ, Kim SW, *et al.* First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. *JAMA Oncol* 2016;2:305-12.
19. Halmos B, Pennell NA, Fu P, *et al.* Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. *Oncologist* 2015;20:1298-303.
20. Soria JC, Wu YL, Nakagawa K, *et al.* Gefitinib plus chemotherapy versus placebo plus chemotherapy in

- EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. *Lancet Oncol* 2015;16:990-8.
21. Soria JC, Kim S, Wu Y, et al. Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC resistant to first-line gefitinib: IMPRESS T790M subgroup analysis. 16th World Conference on Lung Cancer. Denver, 2015.
 22. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med* 2015;372:1689-99.
 23. Janjigian YY, Smit EF, Groen HJ, et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. *Cancer Discov* 2014;4:1036-45.

Cite this article as: Bhateja P, Sharma N. Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question? *Ann Transl Med* 2016;4(Suppl 1):S31. doi: 10.21037/atm.2016.09.45